AIRLINK 77.84 Decreased By ▼ -2.55 (-3.17%)
BOP 4.87 Decreased By ▼ -0.05 (-1.02%)
CNERGY 4.28 Decreased By ▼ -0.07 (-1.61%)
DFML 45.00 Decreased By ▼ -0.51 (-1.12%)
DGKC 85.97 Decreased By ▼ -2.83 (-3.19%)
FCCL 22.45 Decreased By ▼ -1.11 (-4.71%)
FFBL 32.00 Decreased By ▼ -1.00 (-3.03%)
FFL 9.50 Decreased By ▼ -0.07 (-0.73%)
GGL 10.09 Decreased By ▼ -0.18 (-1.75%)
HASCOL 6.55 Decreased By ▼ -0.16 (-2.38%)
HBL 112.00 Decreased By ▼ -1.00 (-0.88%)
HUBC 141.20 Decreased By ▼ -1.36 (-0.95%)
HUMNL 10.97 Decreased By ▼ -0.93 (-7.82%)
KEL 4.85 Decreased By ▼ -0.19 (-3.77%)
KOSM 4.35 Decreased By ▼ -0.15 (-3.33%)
MLCF 38.25 Decreased By ▼ -0.68 (-1.75%)
OGDC 128.89 Decreased By ▼ -3.11 (-2.36%)
PAEL 25.51 Decreased By ▼ -0.24 (-0.93%)
PIBTL 6.36 Decreased By ▼ -0.21 (-3.2%)
PPL 117.50 Decreased By ▼ -2.05 (-1.71%)
PRL 25.80 Decreased By ▼ -0.30 (-1.15%)
PTC 13.74 Decreased By ▼ -0.32 (-2.28%)
SEARL 57.09 Decreased By ▼ -0.42 (-0.73%)
SNGP 64.99 Decreased By ▼ -1.11 (-1.68%)
SSGC 10.00 Decreased By ▼ -0.19 (-1.86%)
TELE 8.12 Decreased By ▼ -0.20 (-2.4%)
TPLP 10.35 Decreased By ▼ -0.21 (-1.99%)
TRG 65.24 Decreased By ▼ -2.91 (-4.27%)
UNITY 26.85 Decreased By ▼ -0.28 (-1.03%)
WTL 1.34 Decreased By ▼ -0.01 (-0.74%)
BR100 7,835 Decreased By -96.8 (-1.22%)
BR30 25,245 Decreased By -504.5 (-1.96%)
KSE100 74,667 Decreased By -908.6 (-1.2%)
KSE30 23,919 Decreased By -292.9 (-1.21%)

A US pharmaceutical firm has identified a new subtype of the human immunodeficiency virus (HIV), and said the finding showed that cutting edge genome sequencing is helping researchers stay ahead of mutations.

The strain, HIV-1 Group M subtype L, has been recorded in three people from blood samples taken between the 1980s and 2001, all in the Democratic Republic of Congo, Abbott laboratories told AFP on Thursday.

To classify a new subtype, three cases must be discovered independently, according to guidelines issued in 2000.

Group M is the most prevalent form of the HIV-1 virus. Subtype L is now the 10th of this group and the first to be identified since the guidelines were issued.

Antiretroviral drugs, which today can reduce the viral load of an HIV carrier to the point at which the infection is both undetectable and cannot be transmitted further, have generally performed well against a variety of subtypes, according to research. But there is also some evidence of subtype differences in drug resistance.

"Since subtype L is part of the major group of HIV, Group M, I would expect current treatments to work with it," Mary Rodgers, a principal scientist and head of the Global Viral Surveillance Program at Abbott told AFP.

Copyright Agence France-Presse, 2019

Comments

Comments are closed.